Summary of randomized clinical trials investigating the effects of vitamin D supplementation on CV risk
| Authors | Year | Intervention (patient number) | Outcome(s) | Results |
|---|---|---|---|---|
| Pittas et al. D2d study182 | 2019 | Cholecalciferol 4000 IU/die i.m (1211patients with pre-diabetes) |
|  |
| de Boer et al. VITAL trial183 | 2019 | Cholecalciferol 2000 IU/die i.m (333 patients with diabetes) |
| |
| Neale et al. D-Health trial185 | 2022 | Cholecalciferol 60 000 IU/month i.m (10662 older people and control group) |
| |
| Theiler-Schwetz et al. Styrian Vitamin D Hypertension Trial184 | 2022 | Cholecalciferol 2800 IU/die i.m (100 hypertensive patients and control group) |
|  |
| Authors | Year | Intervention (patient number) | Outcome(s) | Results |
|---|---|---|---|---|
| Pittas et al. D2d study182 | 2019 | Cholecalciferol 4000 IU/die i.m (1211patients with pre-diabetes) |
| |
| de Boer et al. VITAL trial183 | 2019 | Cholecalciferol 2000 IU/die i.m (333 patients with diabetes) |
| |
| Neale et al. D-Health trial185 | 2022 | Cholecalciferol 60 000 IU/month i.m (10662 older people and control group) |
| |
| Theiler-Schwetz et al. Styrian Vitamin D Hypertension Trial184 | 2022 | Cholecalciferol 2800 IU/die i.m (100 hypertensive patients and control group) |
| |
CI, confidence interval; OR, odds ratio; HR, hazard ratio; eGFR, estimated glomerular filtration rate; ACR, albumin–creatinine ratio; BP, blood pressure; PWV, pulse wave velocity.
Summary of randomized clinical trials investigating the effects of vitamin D supplementation on CV risk
| Authors | Year | Intervention (patient number) | Outcome(s) | Results |
|---|---|---|---|---|
| Pittas et al. D2d study182 | 2019 | Cholecalciferol 4000 IU/die i.m (1211patients with pre-diabetes) |
| |
| de Boer et al. VITAL trial183 | 2019 | Cholecalciferol 2000 IU/die i.m (333 patients with diabetes) |
| |
| Neale et al. D-Health trial185 | 2022 | Cholecalciferol 60 000 IU/month i.m (10662 older people and control group) |
| |
| Theiler-Schwetz et al. Styrian Vitamin D Hypertension Trial184 | 2022 | Cholecalciferol 2800 IU/die i.m (100 hypertensive patients and control group) |
| |
| Authors | Year | Intervention (patient number) | Outcome(s) | Results |
|---|---|---|---|---|
| Pittas et al. D2d study182 | 2019 | Cholecalciferol 4000 IU/die i.m (1211patients with pre-diabetes) |
| |
| de Boer et al. VITAL trial183 | 2019 | Cholecalciferol 2000 IU/die i.m (333 patients with diabetes) |
| |
| Neale et al. D-Health trial185 | 2022 | Cholecalciferol 60 000 IU/month i.m (10662 older people and control group) |
| |
| Theiler-Schwetz et al. Styrian Vitamin D Hypertension Trial184 | 2022 | Cholecalciferol 2800 IU/die i.m (100 hypertensive patients and control group) |
| |
CI, confidence interval; OR, odds ratio; HR, hazard ratio; eGFR, estimated glomerular filtration rate; ACR, albumin–creatinine ratio; BP, blood pressure; PWV, pulse wave velocity.
